Affiliated with a Castle Connolly Top Hospital
Who is Dr. Ganjoo, Medical Oncologist in Stanford, CA?
Dr. Kristen Ganjoo, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. She is board certified. Dr. Ganjoo completed her residency at Indiana University. Dr. Ganjoo is fluent in English and Persian, and is currently seeing new patients. Dr. Ganjoo’s practice accepts Kaiser Permanente, Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Ganjoo’s office at (650) 723-4000.
What are Areas of Expertise for Dr. Ganjoo?
Dr. Kristen Ganjoo, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Ganjoo empowers patients to confidently navigate their health journey, specializing in Sarcoma-Soft Tissue, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Ganjoo is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Ganjoo go to medical school and complete their residency?
Fellowship: Indiana University / School of Medicine
Residency: Indiana University
Is Dr. Ganjoo board certified as a Medical Oncologist?
Yes, Dr. Kristen Ganjoo, MD is board certified by the American Board of Internal Medicine since 2000
What languages does Dr. Ganjoo speak?
Dr. Ganjoo and their clinical team can communicate with patients in the following languages:
English
Persian
What conditions does a Medical Oncologist like Dr. Ganjoo typically treat?
As a Medical Oncologist, Dr. Ganjoo diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Ganjoo. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Soft Tissue Sarcoma
- Cancer
- Connective Tissue Disorder
- Malignant Soft Tissue Tumor
- Connective Tissue Cancer
- Soft Tissue Cancer
ICD-10 Codes:
- C499: Malignant neoplasm of connective and soft tissue, unspecified
Also known as:
- Uterine Cancer
- Endometrial Cancer Treatment (PDQ®)
- Malignant Uterine Tumor
- Uterine Carcinoma
- Cancer of the Uterus
ICD-10 Codes:
- C55: Malignant neoplasm of uterus, part unspecified
Also known as:
- Bone Cancer
- Cancer
- Primary Bone Cancer
- Malignant Bone Tumor
- Bone Sarcoma
- Osteosarcoma
ICD-10 Codes:
- C419: Malignant neoplasm of bone and articular cartilage, unspecified
Also known as:
- Gastrointestinal Stromal Tumor
- Gastrointestinal stromal tumor
- GIST
- GI stromal tumor
- Stomach and bowel tumor
ICD-10 Codes:
- C49A0: Gastrointestinal stromal tumor, unspecified site
Also known as:
- Desmoid Tumor
- Desmoid tumor
- Aggressive Fibromatosis
- Deep Fibromatosis
- Desmoid Fibromatosis
ICD-10 Codes:
- D48119: Desmoid tumor of unspecified site
What procedures does a Medical Oncologist like Dr. Ganjoo typically perform?
As a Medical Oncologist, Dr. Ganjoo performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Ganjoo. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Blood Transfusion
- Blood Transfusion and Donation
- Blood product transfusion
- Red blood cell transfusion
- Plasma transfusion
CPT Codes:
- 36430: Transfusion, blood or blood components
Also known as:
- Declotting of Vascular Access Device
- Catheter declotting
- Thrombolytic therapy for catheter
- Blocked port-a-cath treatment
- Vascular access device unblocking
CPT Codes:
- 36593: Declotting by thrombolytic agent of implanted vascular access device or catheter
Also known as:
- Swallowing Therapy
- Dysphagia Treatment
- Feeding Therapy
- Oral Function Therapy
CPT Codes:
- 92526: Treatment of swallowing dysfunction and/or oral function for feeding
Does Dr. Ganjoo accept my insurance?
Dr. Ganjoo accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Ganjoo accept in Stanford, CA?
Dr. Ganjoo in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Medicaid
Medicare
Santa Cruz County
State of California
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Ganjoo's office located?
Recognitions
Publications
Gastrointestil stromal tumors, version 2.2014.
, 2014
Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines
, 2014
A multicenter phase II study of pazopanib in patients with advanced gastrointestil stromal tumors
, 2014
R1507, a Monoclol Antibody to the Insulin-Like Growth Factor 1 Receptor
, 2011
Current and Emerging Pharmacological Treatments for Gastrointestil Stromal Tumour
, 2011
A Phase I Study of the Safety
, 2011
Soft Tissue Sarcoma
, 2010
NCCN Task Force Report: Update on the Magement of Patients with Gastrointestil Stromal Tumors
, 2010
Acute myeloid leukemia in patients with gastrointestil stromal tumors treated with Gleevec
, 2009
Bevacizumab and cyclosphosphamide, doxorubicin
, 2014
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early
, 2012
Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines
, 2012
Cardiac toxicity associated with bevacizumab
, 2012
Maintence Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
, 2012
Results of a Phase 1 Study of AME-133v (LY2469298)
, 2012
The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study
, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
, 2010
I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (Zevali (R)) Therapy of Low-Grade Refractory
, 2010
Coordite Expression of Colony-Stimulating Factor-1
, 2009
The importance of angiogenesis markers
, 2008
A phase II study of single agent gemcitabine
, 2005
Unusual locations of involvement by maligncies - Case 1. Testicular plasmacytoma
, 2003
Germ cell tumor associated primitive neuroectodermal tumors
, 2001
Results of modern therapy for patients with mediastil nonseminomatous germ cell tumors
, 2000
Primary mediastil nonseminomatous germ cell tumors
, 1999
Lung cancer presenting with solitary bone metastases - Case 1
, 1999
Gastrointestinal stromal tumors, version 2.2014.
, 2014
Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines
, 2014
A multicenter phase II study of pazopanib
, 2014
R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor
, 2011
Current and Emerging Pharmacological Treatments for Gastrointestinal Stromal Tumour
, 2011
A Phase I Study of the Safety
, 2011
New Developments in Targeted Therapy for Soft Tissue Sarcoma
, 2010
Soft Tissue Sarcoma
, 2010
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
, 2010
Antiangiogenesis Agents in the Treatment of Soft Tissue Sarcomas
, 2010
Trabectedin: an anticancer drug from the sea
, 2009
Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec
, 2009
Bevacizumab and cyclosphosphamide, doxorubicin
, 2014
The Treatment Outcome for Adult Patients with Ewing's Sarcoma.
, 2013
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early
, 2012
Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines
, 2012
Cardiac toxicity associated with bevacizumab
, 2012
Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
, 2012
Results of a Phase 1 Study of AME-133v (LY2469298)
, 2012
The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study
, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
, 2010
I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory
, 2010
Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory
, 2010
A phase II first line study of gemcitabine
, 2009
Coordinate Expression of Colony-Stimulating Factor-1
, 2009
A phase II first-line study of gemcitabine, carboplatin
Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor.
, 2009
Breast angiosarcomas: Case series and expression of vascular endothelial growth factor
, 2009
Opportunistic enteroviral meningoencephalitis
, 2009
The importance of angiogenesis markers
, 2008
Review of erlotinib in the treatement of advanced non-small cell lung cancer
Review of erlotinib in the treatment of advanced non-small cell lung cancer.
, 2007
Non-Hodgkin lymphoma of the breast
, 2007
Antiangiogenesis: A new approach to the treatment of lymphoma
, 2007
Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety
, 2006
Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein
, 2006
A phase II study of single agent gemcitabine
, 2005
Unusual locations of involvement by malignancies - Case 1. Testicular plasmacytoma
, 2003
Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer
, 2003
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer
, 2002
Germ cell tumor associated primitive neuroectodermal tumors
, 2001
Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors
, 2000
Positron emission tomography scans in the evaluation of postchemotherapy residual m
, 1999
Primary mediastinal nonseminomatous germ cell tumors
, 1999
Lung cancer presenting with solitary bone metastases - Case 1
, 1999
What is Dr. Ganjoo's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Ganjoo's National Provider Identifier (NPI) number is 1669563391.
What common questions do patients ask about Dr. Ganjoo?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Ganjoo
What is Dr. Kristen Ganjoo's specialty?
Dr. Ganjoo is a Medical Oncologist near Stanford, CA.
What does a Medical Oncologist do?
An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options.
Is this Dr. Kristen Ganjoo affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Ganjoo is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Medical Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Medical Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Kristen Ganjoo accepting new patients in Stanford, CA?
Yes, Dr. Kristen Ganjoo is accepting new patients at this time.
Does Dr. Kristen Ganjoo offer online booking?
Please contact Dr. Ganjoo's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Kristen Ganjoo?
Please contact Dr. Ganjoo's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Kristen Ganjoo have?
Dr. Kristen Ganjoo is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patients
Medical Oncologist
Accepting patients